Key result
Daily low-dose pentylenetetrazol improved long-term recognition memory, promoted safer decision-making, and increased non-rapid eye movement sleep in a Down syndrome mouse model.
Why the study?
Down syndrome involves cognitive disabilities without drug therapies, and the effects of GABA antagonist treatment on sleep and decision-making in DS models remained to be evaluated.
Does pentylenetetrazol improve memory, decision-making, and sleep in a Down syndrome mouse model?
Does pentylenetetrazol improve memory, decision-making, and sleep in a Down syndrome mouse model?
Short-term treatment with a GABA antagonist improves long-term memory, decision-making, and sleep in a mouse model of Down syndrome.
Hypothesis-generating for GABA antagonism in Down syndrome models; leaves open human translation and safety.
Down syndrome (DS) is a common genetic condition affecting people worldwide. It involves cognitive disabilities for which there are no drug therapies. The Ts65Dn mouse model of DS shows cognitive impairment due to a reduction in neuron number and connectivity as well as excessive neuronal activity, as γ-aminobutyric acid (GABA) antagonist treatment restores memory in these mice. Our study showed the effects of GABA antagonist treatment on sleep and decision-making in Ts65Dn mice. We administered a daily, low oral dose of pentylenetetrazol (PTZ) in milk to Ts65Dn mice for 17 days. Decision-making was tested with and without PTZ treatment. Short and long-term memories were tested before, immediately after, and 1 month following PTZ treatment. Electro-encephalography was also recorded at these three time points to study the effect of the treatment on sleep. We showed that PTZ treatment improved long-term recognition, but not short term memory and led to more Ts65Dn mice showing safer decision-making behavior. PTZ treatment showed a moderate and only global beneficial effect on sleep by decreasing the global amount of wake and increasing non-rapid eye movement sleep in the Ts65Dn mice, which may explain the observed cognitive improvements. These results bring new knowledge on the role of GABA in sleep, memory consolidation, and decision-making abilities in DS.
No takes yet. Share an insight, caveat, or question.
Pittaras et al. (2024) studied Down syndrome. Pentylenetetrazol (PTZ) vs. Without PTZ treatment was evaluated on Sleep quality, memory, and decision-making. Daily low-dose pentylenetetrazol improved long-term recognition memory, promoted safer decision-making, and increased non-rapid eye movement sleep in a Down syndrome mouse model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: